Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | SCD | O00767 | 1/20 | 0.65 |
| ▸ | AGER | Q15109 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290771 | 0.83 | NPC1 (0.79) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3200814 | 0.81 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL28801036 | 0.81 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3223685 | 0.81 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2307971 | 0.81 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL4293350 | 0.81 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL13988355 | 0.81 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL13988416 | 0.81 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL2628996 | 0.81 | NPC1 (0.76) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL995829 | 0.81 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284267-B1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | SANKYO CO (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | NAT1, ERG28, DPM1 | RAB9A 1988/4885NPC1 361/4885SMN1; SMN2 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.